JP7681025B2 - 抗ヒトｈｖｅｍ（ｔｎｆｒｓｆ１４）抗体およびそれらの使用 - Google Patents

抗ヒトｈｖｅｍ（ｔｎｆｒｓｆ１４）抗体およびそれらの使用 Download PDF

Info

Publication number
JP7681025B2
JP7681025B2 JP2022538834A JP2022538834A JP7681025B2 JP 7681025 B2 JP7681025 B2 JP 7681025B2 JP 2022538834 A JP2022538834 A JP 2022538834A JP 2022538834 A JP2022538834 A JP 2022538834A JP 7681025 B2 JP7681025 B2 JP 7681025B2
Authority
JP
Japan
Prior art keywords
hvem
human
antibody
seq
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022538834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522520A (ja
JP2023522520A5 (https=
Inventor
ブーン，ルイ
ヨハネス シモンズ，ペトルス
マルセル テオドロス デン，ハルトフ
Original Assignee
ジェイジェイピー バイオロジクス エスピー．ゼット オー．オー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジェイジェイピー バイオロジクス エスピー．ゼット オー．オー． filed Critical ジェイジェイピー バイオロジクス エスピー．ゼット オー．オー．
Publication of JP2023522520A publication Critical patent/JP2023522520A/ja
Publication of JP2023522520A5 publication Critical patent/JP2023522520A5/ja
Application granted granted Critical
Publication of JP7681025B2 publication Critical patent/JP7681025B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022538834A 2019-12-24 2020-12-24 抗ヒトｈｖｅｍ（ｔｎｆｒｓｆ１４）抗体およびそれらの使用 Active JP7681025B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19219684 2019-12-24
EP19219684.8 2019-12-24
PCT/NL2020/050817 WO2021133170A1 (en) 2019-12-24 2020-12-24 Anti-human hvem (tnfrsf14) antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2023522520A JP2023522520A (ja) 2023-05-31
JP2023522520A5 JP2023522520A5 (https=) 2025-04-08
JP7681025B2 true JP7681025B2 (ja) 2025-05-21

Family

ID=69061152

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022538834A Active JP7681025B2 (ja) 2019-12-24 2020-12-24 抗ヒトｈｖｅｍ（ｔｎｆｒｓｆ１４）抗体およびそれらの使用

Country Status (10)

Country Link
US (1) US12503516B2 (https=)
EP (1) EP4081541A1 (https=)
JP (1) JP7681025B2 (https=)
KR (1) KR20220128363A (https=)
CN (1) CN115087672A (https=)
AU (1) AU2020414265A1 (https=)
BR (1) BR112022012725A2 (https=)
CA (1) CA3162656A1 (https=)
MX (1) MX2022007855A (https=)
WO (1) WO2021133170A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4265639A2 (en) * 2020-12-15 2023-10-25 Medytox Inc. Anti-hvem antibody, and composition and method associated with same
US20240317871A1 (en) * 2020-12-30 2024-09-26 Immunomic Therapeutics, Inc. Anti-HVEM Antibodies
CN116715769B (zh) * 2022-05-26 2024-06-25 四川大学 抗hvem抗体、制备方法及其用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010106051A1 (en) 2009-03-17 2010-09-23 Universite De La Mediterranee Btla antibodies and uses thereof
JP2011521887A (ja) 2007-06-01 2011-07-28 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エト・ドゥ・ラ・ルシェルシュ・メディカル） 血液悪性腫瘍および自己免疫疾患を治療するためのｈｖｅｍのリガンド
JP2016518436A (ja) 2013-05-17 2016-06-23 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 治療において使用するための、ｂｔｌａ／ｈｖｅｍ相互作用のアンタゴニスト

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
DK1399484T3 (da) 2001-06-28 2010-11-08 Domantis Ltd Dobbelt-specifik ligand og anvendelse af denne
AU2003244817B2 (en) 2002-06-28 2010-08-26 Domantis Limited Antigen-binding immunoglobulin single variable domains and dual-specific constructs
US8188232B1 (en) * 2004-11-15 2012-05-29 Washington University In St. Louis Compositions and methods for modulating lymphocyte activity
WO2010006071A1 (en) * 2008-07-08 2010-01-14 La Jolla Institute For Allergy And Immunology Hvem/btla, hvem/cd160 and hvem/gd cis complexes and methods of use
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
WO2006090385A2 (en) * 2005-02-22 2006-08-31 Ramot At Tel-Aviv University Ltd. Protease inhibitors and method of screening thereof
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
TWI427085B (zh) * 2011-11-02 2014-02-21 國立成功大學 活化纖維蛋白溶酶原之抗體、其用途以及含有其之製劑
EP2985294A1 (en) * 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
CA2981304C (en) * 2015-04-02 2024-01-02 Memorial Sloan Kettering Cancer Center Tnfrsf14/hvem proteins and methods of use thereof
US10562952B2 (en) * 2015-09-10 2020-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 chimeric antigen receptors
US10617720B2 (en) * 2016-10-20 2020-04-14 Miltenyi Biotech, GmbH Chimeric antigen receptor specific for tumor cells
US12036242B2 (en) * 2018-07-05 2024-07-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. CAR T cells that target B-cell antigens
WO2020095249A1 (en) * 2018-11-07 2020-05-14 Crispr Therapeutics Ag Anti-liv1 immune cell cancer therapy
BR112021021645A2 (pt) * 2019-04-29 2021-12-21 4C Biomed Ltd Anticorpos anti-hvem e uso dos mesmos.
JP7716393B2 (ja) * 2019-10-04 2025-07-31 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗ｋｉｒ３ｄｌ３抗体およびそれらの使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011521887A (ja) 2007-06-01 2011-07-28 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エト・ドゥ・ラ・ルシェルシュ・メディカル） 血液悪性腫瘍および自己免疫疾患を治療するためのｈｖｅｍのリガンド
WO2010106051A1 (en) 2009-03-17 2010-09-23 Universite De La Mediterranee Btla antibodies and uses thereof
JP2016518436A (ja) 2013-05-17 2016-06-23 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 治療において使用するための、ｂｔｌａ／ｈｖｅｍ相互作用のアンタゴニスト

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
del RIO Maria-Luisa et al.，Selective Blockade of Herpesvirus Entry Mediator-B and T Lymphocyte Attenuator Pathway Ameliorates Acute Graft-versus-Host Reaction，J. Immunol.，2012年，vol. 188，pp. 4885-4896

Also Published As

Publication number Publication date
KR20220128363A (ko) 2022-09-20
US20230052646A1 (en) 2023-02-16
MX2022007855A (es) 2022-09-23
WO2021133170A1 (en) 2021-07-01
US12503516B2 (en) 2025-12-23
AU2020414265A1 (en) 2022-07-21
BR112022012725A2 (pt) 2022-11-16
JP2023522520A (ja) 2023-05-31
EP4081541A1 (en) 2022-11-02
CN115087672A (zh) 2022-09-20
CA3162656A1 (en) 2021-07-01

Similar Documents

Publication Publication Date Title
US11840571B2 (en) Methods of using bispecific molecules having immunoreactivity with PD-1 and CTLA-4
AU2017317227B2 (en) Anti-Tim-3 antibodies and use thereof
JP7681025B2 (ja) 抗ヒトｈｖｅｍ（ｔｎｆｒｓｆ１４）抗体およびそれらの使用
US10618962B2 (en) Anti-CTLA4 antibodies
CN112552401B (zh) 抗pd1抗体及其作为治疗剂与诊断剂的用途
US20170233472A1 (en) ROR1-Binding Molecules, and Methods of Use Thereof
JP2021508676A (ja) 抗ｔｉｇｉｔ抗体並びに治療剤及び診断剤としてのその使用
WO2016122701A1 (en) Anti-dr5 antibodies and molecules comprising dr5-binding domains thereof
JP2023522520A5 (https=)
KR20190026766A (ko) 항-il-22r 항체
AU2022301381A1 (en) Anti-cd3 antibody and use thereof
JP2026508244A (ja) 抗Ｎｅｃｔｉｎ－４抗体及びそれを含む多重特異性抗体
JP2019048804A (ja) 抗ｐｄ−１抗体並びにその治療及び診断のための使用
EA049801B1 (ru) Антитела против hvem человека (tnfrsf14) и их применение
RU2831786C2 (ru) БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К Vβ17/CD123
NZ782254A (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
EA043373B1 (ru) Биспецифичные молекулы, обладающие иммунореактивностью в отношении pd-1 и ctla-4, и способы их применения
HK1217501B (zh) 抗pd1抗体及其作为治疗剂与诊断剂的用途
EA044655B1 (ru) Антитела против pd1 и их применение в качестве терапевтических и диагностических средств

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250212

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250328

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250414

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250509

R150 Certificate of patent or registration of utility model

Ref document number: 7681025

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150